Literature DB >> 27374366

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

David W Dawson1, Martin E Fernandez-Zapico2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27374366      PMCID： PMC6042851          DOI： 10.1053/j.gastro.2016.06.032

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  18 in total

Review 1.  What we have learned about pancreatic cancer from mouse models.

Authors:  Pedro A Pérez-Mancera; Carmen Guerra; Mariano Barbacid; David A Tuveson
Journal:  Gastroenterology       Date:  2012-03-08       Impact factor: 22.682

2.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

Authors:  Lola Rahib; Benjamin D Smith; Rhonda Aizenberg; Allison B Rosenzweig; Julie M Fleshman; Lynn M Matrisian
Journal:  Cancer Res       Date:  2014-06-01       Impact factor: 12.701

3.  Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Authors:  Dung T Le; Andrea Wang-Gillam; Vincent Picozzi; Tim F Greten; Todd Crocenzi; Gregory Springett; Michael Morse; Herbert Zeh; Deirdre Cohen; Robert L Fine; Beth Onners; Jennifer N Uram; Daniel A Laheru; Eric R Lutz; Sara Solt; Aimee Luck Murphy; Justin Skoble; Ed Lemmens; John Grous; Thomas Dubensky; Dirk G Brockstedt; Elizabeth M Jaffee
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

Review 4.  Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.

Authors:  Yawen Zheng; Yan Dou; Lili Duan; Changsheng Cong; Aiqin Gao; Qinghua Lai; Yuping Sun
Journal:  Cell Immunol       Date:  2015-02-10       Impact factor: 4.868

5.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas.

Authors:  B A Ruggeri; L Huang; M Wood; J Q Cheng; J R Testa
Journal:  Mol Carcinog       Date:  1998-02       Impact factor: 4.784

Review 6.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Aram F Hezel; Alec C Kimmelman; Ben Z Stanger; Nabeel Bardeesy; Ronald A Depinho
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

7.  Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.

Authors:  Y Homma; K Taniguchi; M Nakazawa; R Matsuyama; R Mori; K Takeda; Y Ichikawa; K Tanaka; I Endo
Journal:  Clin Transl Oncol       Date:  2013-07-17       Impact factor: 3.405

8.  Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.

Authors:  Riki Okita; Diana Wolf; Koichiro Yasuda; Ai Maeda; Takuro Yukawa; Shinsuke Saisho; Katsuhiko Shimizu; Yoshiyuki Yamaguchi; Mikio Oka; Eiichi Nakayama; Andreas Lundqvist; Rolf Kiessling; Barbara Seliger; Masao Nakata
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

9.  Effect of surgery on pancreatic tumor-dependent lymphocyte asset: modulation of natural killer cell frequency and cytotoxic function.

Authors:  Francesco Iannone; Alessandra Porzia; Giovanna Peruzzi; Patrizia Birarelli; Bernardina Milana; Luca Sacco; Giuseppe Dinatale; Nadia Peparini; Giampaolo Prezioso; Simone Battella; Roberto Caronna; Stefania Morrone; Gabriella Palmieri; Fabrizio Mainiero; Piero Chirletti
Journal:  Pancreas       Date:  2015-04       Impact factor: 3.327

Review 10.  Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy.

Authors:  Kelly Kersten; Camilla Salvagno; Karin E de Visser
Journal:  Front Immunol       Date:  2015-10-07       Impact factor: 7.561
View more
  3 in total

Review 1.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 2.  The Potential for Circulating Tumor Cells in Pancreatic Cancer Management.

Authors:  Michael Pimienta; Mouad Edderkaoui; Ruoxiang Wang; Stephen Pandol
Journal:  Front Physiol       Date:  2017-06-02       Impact factor: 4.566

Review 3.  Understanding and Targeting Natural Killer Cell-Cancer-Associated Fibroblast Interactions in Pancreatic Ductal Adenocarcinoma.

Authors:  Zoe X Malchiodi; Louis M Weiner
Journal:  Cancers (Basel)       Date:  2021-01-22       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.